

# **Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update**

STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, at 8:30 am ET before the U.S. financial markets open.

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Date: Monday, November 15, 2021

Time: 8:30 a.m. ET

Toll free (U.S. and International): 877-790-1503

Conference ID: 13724324

## **About Ibezapolstat**

Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is the first of a new class of DNA polymerase IIIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes *C. difficile* but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome.

In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and is preparing to start enrollment of its Phase 2b vancomycin-controlled efficacy study in a 1:1 randomized trial of a total of 64 patients with CDI.

The CDC has designated *C. difficile* as an urgent threat highlighting the need for new antibiotics to treat CDI.

## **About Acurx Pharmaceuticals, Inc.**

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase III C enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including *Clostridioides difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant *Streptococcus pneumoniae* (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline please visit [www.acurxpharma.com](http://www.acurxpharma.com).


**Investor Contact:**

Acurx Pharmaceuticals, Inc.

David P. Luci, President & CEO

Tel: 917-533-1469

Email: [davidluci@acurxpharma.com](mailto:davidluci@acurxpharma.com)

 View original content: <https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-discuss-2021-third-quarter-financial-results-on-november-15-2021-conference-call-and-provide-business-update-301408715.html>

SOURCE Acurx Pharmaceuticals, Inc.